key: cord-0887554-pwr7fhao
authors: La Milia, Vincenzo; Tonolo, Silvia; Luzzaro, Francesco; Bonato, Claudio; Casartelli, Donatella; Limardo, Monica; Longhi, Selena; Ravasi, Chiara; Viganò, Sara; Cavalli, Andrea
title: Humoral and T-cell response to SARS-CoV-2 mRNA BNT162b2 vaccination in a cohort of kidney transplant recipients and their cohabitant living kidney donor partners
date: 2022-01-13
journal: Clin Kidney J
DOI: 10.1093/ckj/sfac010
sha: 17f1692eeda07f9e580324c4384abdf1d0196d48
doc_id: 887554
cord_uid: pwr7fhao

nan

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a high rate of mortality in kidney transplant recipients (KTRs) [1] . The current vaccine strategy for KTRs appears not to provide effective protection against coronavirus disease 2019 (COVID-19) [2] and the occurrence of severe COVID-19 in some vaccinated KTRs may suggest a lack of immunity [3] .

At this time, one way to protect KTRs might be to vaccinate their immediate family members, especially their spouses. However, it is not known how effective the SARS-CoV-2 vaccine is in the cohabitants of KTRs.

We prospectively investigated KTRs and their respective cohabitant living kidney donor partners (LKDPs) who were vaccinated with two doses of the Pfizer-BioNTech messenger RNA (mRNA) BNT162b2 (Comirnaty) vaccine. Criteria for exclusion were as follows: divorced or not closely cohabiting couples and anti-SARS-CoV-2 immunoglobulin G (IgG) titer above the positivity threshold (>15 AU/mL) at administration of the first dose of vaccine.

This study was approved by the local ethics committee. After written informed consent, between 22 March and 16 April 2021, on the same days, KTRs and their cohabitant LKDPs were vaccinated with two doses of Pfizer-BioNTech mRNA BNT162b2 SARS-CoV-2 vaccine 21 days apart.

The humoral immune response was assessed at the time of administration of the first and second vaccine dose and then 1 and 3 months after the administration of the second vaccine dose. Cellular immunity was assessed 3 months after administration of the second vaccine dose.

Sera of all KTRs and LKDPs were tested using the Liaison® assay (DiaSorin, Saluggia, Italy), detecting IgG against two spike glycoprotein (S1 and S2) antigens. A concentration of SARS-CoV-2 S1/S2 IgG <12 AU/mL is considered negative, a concentration between 12 and 15 AU/mL is considered uncertain and a concentration >15 AU/mL is considered positive.

As far as cellular immunity response is concerned, spikespecific CD4 + and CD8 + T-cell responses were quantified in the circulation of the KTRs and LKDPs using the QuantiFERON SARS-CoV2 test (Qiagen, Venlo, The Netherlands), a commercially available interferon γ (INF-ᵧ) releasing assay (IGRA); according to the manufacturer, a concentration of INF-ᵧ ≥0.15-0.20 IU/mL is considered positive.

A total of 18 KTRs (females 44%, age 59 ± 8 years) and their respective cohabitant LKDPs (females 56%, age 59 ± 8 years) were included in the study (Table 1) At the administration of the second dose of vaccine, only one KTR had an anti-SARS-Cov-2 IgG titer (55.8 AU/mL) above the As far as cellular immunity response is concerned, 2 (11%) KTRs showed a specific T-cell response 3 months after the second dose of vaccine, while 16 (89%) LKDPs showed a specific T-cell response.

The current vaccine strategy, even after a third booster dose [4] , appears not to provide effective protection against COVID-19 for KTRs, while it provides full protection in LKDPs, indicating that vaccination should be highly recommended in immediate family members of KTRs.

French Nationwide Registry of Solid Organ Transplant Recipients with COVID-19: IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT)

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

French Society of Transplantation: occurrence of severe COVID-19 in vaccinated transplant patients

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series

We are grateful to all patients participating in the study and to all nurses of hemodialysis centers.

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. The authors declare that they have no relevant financial interests.